News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
News

Pharmaceutical Technology Europe
Volume 20, Issue 10

R&D

Breaking the rules!

Has Overton's rule been overturned?

The century old rule of pharmacology that defines how quickly key chemicals pass across cell walls has been challenged by new observations that claim the real transport rates could be up to a hundred times slower than those predicted by Overton's rule.

Overton's rule, first outlined in the 1890s by Ernst Overton, says that the easier it is for a chemical to dissolve in a lipid, the faster it will be transported into a cell. However, using a confocal microscope and an ultramicroelectrode, a team of electrochemists from the University of Warwick (UK) studied what really happens when a chemical crosses a cell membrane. While the acids did diffuse across a lipid membrane, they did so at rates that were diametrically opposite to the predictions of the rule as the most lipophilic molecules were actually transported slowest, at least for the chemicals studied.

Lead researcher on the study, Professor Patrick Unwin, says: "We will now make observations with a range of other chemicals, and with other techniques to further elucidate the molecular basis for our observations. Text books will have to be rewritten to revise a rule that has been relied on for more than a century. Advanced techniques, such as the one we have developed, should give much clearer insight into the action of a wide range of drug molecules, which will be of significant interest to drug developers."

Read more at: http://www.ptemag.com/overton/

An exclusive interview with Patrick Unwin can be read at: http://www.ptemag.com/Unwin/

M&As

Appikon's big buy out

Applikon Biotechnology BV is planning a management buy out of the company to enable the business to continue to build on its existing growth. Sales and Marketing Director Erik Kakes says: "We've all worked really hard for this and I'm looking forward to realizing our full potential in the future."

An exclusive interview with Erik Kakes can be read at: http://www.ptemag.com/applikon/

Recipharm looks to lyophilize

Recipharm has purchased Inotech Labor's lyophilization facilities in Basel (Switzerland). The site will now be operated by the newly formed company Recipharm AG. Thomas Eldered, CEO and Managing Director of Recipharm, says: "Being profitable and cash positive enabled us to move fast during the bidding process and emerge as Inotech Labor's preferred purchaser."

An exclusive interview with Thomas Eldered can be read at: http://www.ptemag.com/recipharm/


ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
When sourcing raw materials and non-GMP intermediates or other chemicals, where are the majority of your suppliers located?
In the United States
In Western Europe
In Central and Eastern Europe
In Japan
In India
In China
In the United States
18%
In Western Europe
19%
In Central and Eastern Europe
3%
In Japan
2%
In India
31%
In China
28%
View Results
Jim MillerOutsourcing OutlookJim Miller Time for a Model Upgrade
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Navigating the Global Pharmaceutical Supply Chain
Faiz kermaniSpotlight Faiz Kermani Reinvigorating European R&D innovation
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Life After Big Pharma
PhRMA Details Its Proposal for Internet and Social-Media Standards
The Unregulated Regulator
Rx-360 Goals Get off the Ground
US and Europe At Risk from Substandard Medicines
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here